TY  - GEN 
AU  - Sánchez-Herrero, E.
AU  - Campos-Silva, C.
AU  - Cáceres-Martell, Y.
AU  - Robado De Lope, L.
AU  - Sanz-Moreno, S.
AU  - Serna-Blasco, R.
AU  - Rodríguez-Festa, A.
AU  - Ares Trotta, D.
AU  - Martín-Acosta, P.
AU  - Patiño, C.
AU  - Coronado, M.J.
AU  - Beneitez, A.
AU  - Jara, R.
AU  - Lago Baameiro, Nerea
AU  - Camino Martinez, Tamara
AU  - Cruz-Bermúdez, A.
AU  - Pardo Pérez, María
AU  - González-Rumayor, V.
AU  - Valés-Gómez, M.
AU  - Provencio, M.
AU  - Romero, A.
PY  - 2022
SN  - 1530-8561
UR  - http://hdl.handle.net/20.500.11940/20683
AB  - Background: ALK rearrangements are present in 5% of nonsmall cell lung cancer (NSCLC) tumors and identify patients who can benefit from ALK inhibitors. ALK fusions testing using liquid biopsies, although challenging, can expand the therapeutic options...
LA  - eng
TI  - ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing
DO  - 10.1093/clinchem/hvac021
KW  - AS Santiago
KW  - IDIS
KW  - CHUS
VL  - 68
ER  -